Condition

Allergy to House Dust Mite

ClinicalTrials.gov condition label

Clinical trials4

Recruiting0

Common interventions11

Lead sponsors shown4

Clinical trials

4 shown

Clinical Trial to Evaluate the Efficacy and Safety of Polymerized, Mannan-Conjugated Dermatophagoides Allergen ExtractNCT05641272 · 2023-11-01

NOT_YET_RECRUITING

Effects of Tregalizumab on Allergen-induced Airway Responses and Airway Inflammation in Asthmatic PatientsNCT04673591 · 2020-12-09

COMPLETED

Effect of a Dietary Fatty Acid Supplementation on Symptoms and Bronchial Inflammation in Patients With AsthmaNCT04109534 · 2019-10-01

UNKNOWN

Role of Indoor Pollutants on House Dust Mite Allergic AsthmaNCT01019291

WITHDRAWN

Common interventions

3,000 MM09BIOLOGICAL19,000 MM09BIOLOGICAL1Bronchial allergen provocation (BAP)DIAGNOSTIC_TEST1Formaldehyde and NO2 (Exposure to indoor pollutants)OTHER1Methacholine testDIAGNOSTIC_TEST1Nasal provocation test (NPT)DIAGNOSTIC_TEST1Peak nasal expiratory flow (PNIF)DIAGNOSTIC_TEST1PlaceboOTHER1Placebo (Exposure to indoor pollutants)OTHER1Placebo sublingualOTHER1TregalizumabDRUG1

Leading sponsors

Inmunotek S.L.1Stefan Zielen1T-Balance Therapeutics GmbH1University Hospital, Strasbourg, France1

Trial status mix

COMPLETED1

NOT_YET_RECRUITING1

UNKNOWN1

WITHDRAWN1

Phase mix

NA2

PHASE22

PHASE31

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.